← Back
Data updated: Jun 28, 2026
BDSI
Specialty Pharmaceuticals
BDSI is a specialty pharmaceutical company with 3 FDA-approved products.
2014
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
FDA Novel Drug Designations
(2017) 1 Novel
See 1 novel approval →
BDSI's Key Drugs
BDSI's core commercial portfolio centers on BELBUCA, SYMPROIC — its most strategically important drugs approved in the last 15 years.
BDSI's Recent FDA Approvals
New NDA/BLA approvals for BDSI over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
BDSI's Therapeutic Areas
Disease areas where BDSI has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
BDSI Pipeline Snapshot
Active clinical trials for BDSI across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BELBUCA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling